Iptacopan, Rituximab — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-12-30 in 3mo
ESTIMATED |
READOUT
Iptacopan in Patients With ANCA Associated Vasculitis
Phase 2 · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis |
NVS NOVARTIS AG | Iptacopan, Rituximab |
ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
|